Efficacy and Tolerability of a Probiotic Ointment
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Sofia Nordh, PhD
- Telefonnummer: +46 (0)8 555 293 00
- E-post: son@biogaianewsciences.com
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria Male and female pediatric patients aged 0.5 years to 15 years with Atopic Dermatitis.
SCORAD Index at D0 = 15 to 50, inclusive. In goodgeneral health as reported by the parent(s)/legal representative(s). Available for the full duration of the study and willing to comply with procedures.
Subjects whose parents or legal representative are willing to sign the informed consent.
Exclusion Criteria Use of phototherapy for atopic dermatitis. Use of systemic corticosteroids within 2 weeks prior to the study. Use of Immunosuppressive or cytostatic drugs within 1 months prior to the study.
Use of antibiotics (topical and systemic) within 15 days prior to the start of the study.
Subjects who are treated with vitamin A-derived compounds or other topical medications for acne in the experimental area during the 30 days prior to the start of the study.
History of sensitivity to the study products, or its components. History or evidence of allergies requiring acute or chronic treatment (except seasonal allergic rhinitis).
Subjects with active infection in atopic dermatitis areas requiring antibiotics, antifungals, or antiviral agents within 7 days before baseline participation in any study that would interfere with the current study.
Fever (temperature> 37.5 °C axillary or equivalent) during 48 hours prior the start of the study.
Pathologies associated with immunodeficiency or cancer processes. Any concurrent dermatologic or medical conditions that may interfere with the investigators ability to assess the subject's response to the study drug or require the continued use of topical corticosteroids.
Subjects who have received the schedule MMR vaccination during the study period or have received the last dose within three weeks prior the start of the study.
Subjects who participates in any study that would interfere with the current study.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Probiotic Ointment
Probiotic Ointment 2x day
|
Probiotic ointment
|
|
Eksperimentell: Comparator Product
Comparator product 2x day
|
Basic lotion
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Primary Endpoint
Tidsramme: 28 days
|
To evaluate the change in SCORAD from baseline to Day 28.
|
28 days
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Secondary Endpoint
Tidsramme: 14 days
|
To evaluate the change in SCORAD from baseline to Day 14
|
14 days
|
|
Secondary Endpoint
Tidsramme: 14 and 28 days
|
To evaluate the change in local SCORAD from baseline to Day 14 and Day 28
|
14 and 28 days
|
|
Secondary Endpoint
Tidsramme: 14 and 28 days
|
To evaluate the change in skin barrier function (TEWL) from baseline to Day 14 and Day 28
|
14 and 28 days
|
|
Secondary Endpoint
Tidsramme: 14 and 28 days
|
To evaluate the change in POEM score from baseline to Day 14 and Day 28
|
14 and 28 days
|
|
Secondary endpoint
Tidsramme: 14 and 28 days
|
To evaluate the change in itch NRS from baseline to Day 14 and Day 28
|
14 and 28 days
|
|
Secondary Endpoint
Tidsramme: 28 days
|
To evaluate the use of topical corticosteroids during the study period
|
28 days
|
|
Secondary Endpoint
Tidsramme: 28 Days
|
To explore changes in skin microbiota between baseline and Day 28
|
28 Days
|
|
Secondary Endpoint
Tidsramme: 28 days
|
To evaluate patient-reported tolerability and reported adverse events during the study period
|
28 days
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- BNS_RD_004
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .